論文リスト(研究内容)|東京大学医学部附属病院

東京大学医学部附属病院 血液・腫瘍内科
東京大学 東京大学医学部附属病院
Loading
東京大学医学部附属病院 血液・腫瘍内科

論文リスト(研究内容)

[2018年] >2017年 >2016年 >2015年 >2014年 >2013年 >2012年 >2011年
  1. Suzuki Y, Honda A, Nakazaki K, Mizuno H, Ikemura M, Shinozaki-Ushiku A, Nakamura F, Fukayama M, Kurokawa M.
    Histological transformation of MALT lymphoma to plasma cell leukemia after rituximab-containing therapy.
    Annals of Hematology. [in press]
    PMID: 29582109
  2. Masamoto Y, Kurokawa M.
    Targeting chronic myeloid leukemia stem cells with prostaglandin E1.
    Stem Cell Investigation. 5:10, 2018
    PMID: 29780814
  3. Yasunaga M, Taoka K, Nakagawa H, Yamada A, Abe H, Nakazaki K, Fukayama M, Koike K, Kurokawa M.
    Eculizumab treatment for ischemic enteritis accompanied with paroxysmal nocturnal hemoglobinuria: a case report and literature review.
    Annals of Hematology. [in press]
    PMID: 29532162
  4. Morita K, Koya J, Toya T, Nakamura F, Kurokawa M.
    Philadelphia chromosome-negative acute promyelocytic leukemia manifesting after long-term imatinib treatment for chronic myeloid leukemia; a case report and literature review.
    Annals of Hematology. 97(6):1105-1109, 2018
    PMID: 29404721
  5. Suzuki Y, Koya J, Ebisawa K, Abe H, Shinozaki-Ushiku A, Nakamura F, Kurokawa M.
    Sequential development of monoclonal B-cell lymphocytosis-derived small lymphocytic lymphoma and plasma cell leukemia.
    Annals of Hematology. 97(5): 917-919, 2018.
    PMID: 29417202
  6. Miyauchi M, Koya J, Arai S, Yamazaki S, Honda A, Kataoka K, Yoshimi A, Taoka K, Kumano K, Kurokawa M.
    ADM8 is an antigen of TKI-resistant CML cells identified by patient-derived induced pluripotent stem cells.
    Stem Cell Reports. 10(3): 1115-1130, 2018.
    PMID: 29429960
  7. Toyama K, Yasumoto A, Nakamura F, Arai S, Kurokawa M.
    The development of acute systemic multiple thrombosis after the remission during systemic glucocorticoid therapy for acquired hemophilia A.
    Intern Med. [in press]
    PMID: 29526954
  8. Morita K, Honda A, Koya J, Toyama K, Ikeda M, Misawa Y, Okugawa S, Nakamura F, Moriya K, Kurokawa M.
    Three cases of Candida fermentati fungemia following hematopoietic stem cell transplantation.
    J Infect Chemother. [in press]
    PMID: 29371065
  9. Maki H, Nannya Y, Imai Y, Yamaguchi S, Kamikubo Y, Ichikawa M, Nakamura F, Kurokawa M.
    Nonmyelomatous ascites resulting from increased secretion of vascular endothelial growth factor in multiple myeloma.
    Intern Med. 57(5):725-727, 2018
    PMID: 29151500
  10. Matsuda K, Toyama K, Toya T, Ikemura M, Nakamura F, Kuromawa M.
    Reactivation of hemophagocytic lymphohistiocytosis triggered by antithymocyte globulin.
    Intern Med. 57(4):583-586, 2018.
    PMID: 29225252


このページの先頭へ




[2017年] >2018年 >2016年 >2015年 >2014年 >2013年 >2012年 >2011年
  1. Kobayashi T, Nannya Y, Ichikawa M, Oritani K, Kanakura Y, Tomita A, Kiyoi H, Kobune M, Kato J, Kawabata H, Shindo M, Torimoto Y, Yonemura Y, Hanaoka N, Nakakuma H, Hasegawa D, Manabe A, Fujishima N, Fujii N, Tanimoto M, Morita Y, Matsuda A, Fujieda A, Katayama N, Ohashi H, Nagai H, Terada Y, Hino M, Sato K, Obara N, Chiba S, Usuki K, Ohta M, Imataki O, Uemura M, Takaku T, Komatsu N, Kitanaka A, Shimoda K, Watanabe K, Tohyama K, Takaori-Kondo A, Harigae H, Arai S, Miyazaki Y, Ozawa K, Kurokawa M; for National Research Group on Idiopathic Bone Marrow Failure Syndromes.
    A nationwide survey of hypoplastic myelodysplastic syndrome (a multicenter retrospective study).
    Am J Hematol. 92:1324-1332, 2017.
    PMID: 28891083
  2. Matsuda K, Taoka K, Jona M, Masuda A, Arai S, Nakamura F, Yatomi Y, Kurokawa M.
    Clinical features of hematological disorders with increased large granular lymphocytes (LGLs): A retrospective study.
    Annals of Hematology. 96:2113-2115, 2017.
    PMID: 29098369
  3. Matsuda K, Koya J, Toyama K, Ikeda M, Arai S, Nakamura F, Okugawa S, Moriya K, Kurokawa M.
    A therapeutic benefit of daptomycin against glycopeptide-resistant gram-positive cocci bloodstream infections under neutropenia.
    J Infect Chemother. 23:788-790, 2017
    PMID: 28743428
  4. Chiba A, Nakamura F, Nakazaki K, Kurokawa M.
    Cytomegalovirus antigenemia and end-organ disease in Japanese patients treated with bendamustine.
    Leuk Lymphoma. 12:1-3, 2017
    PMID: 28697686
  5. Masamoto Y, Arai S, Sato T, Kubota N, Takamoto I, Kadowaki T, Kurokawa M.
    Adiponectin Enhances Quiescence Exit of Murine Hematopoietic Stem Cells and Hematopoietic Recovery Through mTORC1 Potentiation.
    Stem Cells. 35(7):1835-1848, 2017
    PMID: 28480607
  6. Koya J, Ibaraki T, Yamazaki I, Nakamura F, Kurokawa M.
    Acute basophilic leukemia with add(3)(q12) accompanied by histamine excess symptoms.
    Ann Hematol. 96(7):1197-1199, 2017
    PMID: 28424883
  7. Mizuno H, Koya J, Fujioka Y, Ibaraki T, Nakamura F, Hayashi A, Shinozaki-Ushiku A, Akamatsu N, Hasegawa K, Kokudo N, Fukuyama M, Kurokawa M.
    Extranodal NK/T cell lymphoma in a living donor liver transplant recipient.
    Ann Hematol. 96(6):1051-1052, 2017
    PMID: 28280996
  8. Morita K, Nakamura F, Sakuishi K, Yamamoto T, Shimizu J, Tsuji S, Kurokawa M.
    Successful management of chronic myeloid leukemia with a complication of anti-SRP antibody-associated myopathy.
    Leuk Lymphoma. 58(5):1242-1245, 2017
    PMID: 27724131


このページの先頭へ




[2016年] >2018年 >2017年 >2015年 >2014年 >2013年 >2012年 >2011年
  1. Masamoto Y, Kurokawa M.
    Inflammation-induced emergency megakaryopoiesis: inflammation paves the way for platelets.
    Stem Cell Investig 3:16, 2016.
    PMID: 27486586
  2. Sumitomo Y, Koya J, Nakazaki K, Kataoka K, Tsuruta-Kishino T, Morita K, Sato T, Kurokawa M.
    Cytoprotective autophagy maintains leukemia-initiating cells in murine myeloid leukemia.
    Blood 128(12):1614-24, 2016.
    PMID: 27480114
  3. Koya J, Kataoka K, Sato T, Bando M, Kato Y, Tsuruta-Kishino T, Kobayashi H, Narukawa K, Miyoshi H, Shirahige K, and Kurokawa M.
    DNMT3A R882 mutants interact with polycomb proteins to block haematopoietic stem and leukaemic cell differentiation.
    Nat Commun 7:10924, 2016.
    PMID: 27010239
  4. Masamoto Y, Arai S, Sato T, Yoshimi A, Kubota N, Takamoto I, Iwakura Y, Yoshimura A, Kadowaki T, and Kurokawa M.
    Adiponectin enhances antibacterial activity of hematopoietic cells by suppressing bone marrow inflammation.
    Immunity 44(6):1422-33, 2016.
    PMID: 27317261
  5. Ebisawa K, Koya J, Shinozaki-Ushiku A, Nakamura F, and Kurokawa M.
    Paraneoplastic limbic encephalitis in B cell lymphoma unclassifiable with features intermediate between diffuse large B cell lymphoma and classical Hodgkin lymphoma.
    Ann Hematol 95(6):1011-2, 2016.
    PMID: 26984106
  6. Morita K, Nakamura F, Taoka K, Satoh Y, Iizuka H, Masuda A, Seo S, Nannya Y, Yatomi Y, and Kurokawa M.
    Incidentally-detected t(9;22)(q34;q11)/BCR-ABL1- positive clone developing into chronic phase chronic myeloid leukaemia after four years of dormancy.
    Br J Haematol 174(5):815-7, 2016.
    PMID: 26560179
  7. Nakamura F, Nakamura F, Ikemura M, Fukayama M, and Kurokawa M.
    Extraosseous plasmacytoma in the nasal cavity after rituximab therapy against pulmonary MALT lymphoma.
    Ann Hematol 95(10):1733-5, 2016.
    PMID: 26884589
  8. Shinohara A, Honda A, Nukina A, Takaoka K, Tsukamoto A, Hangai S, Kogure Y, Kobayashi T, Yamazaki S, Ueda K, Nakamura F, Nannya Y, and Kurokawa M.
    Acute pericarditis before engraftment in hematopoietic stem cell transplantation.
    Bone Marrow Transplant 51(3):459-61, 2016.
    PMID: 26595074
  9. Toya T, Nannya Y, Hangaishi A, Shiseki M, Shimoyama T, Sakamaki H, Motoji T, Usuki K, Nakamura F, and Kurokawa M.
    Prognostic relevance of CD20 expression in peripheral T-cell lymphomas: a multi-center retrospective study.
    Leuk Lymphoma 57(4):961-4, 2016.
    PMID: 26366623
  10. Yoshimi A, Toya T, Nannya Y, Takaoka K, Kirito K, Ito E, Nakajima H, Hayashi Y, Takahashi T, Moriya-Saito A, Suzuki K, Harada H, Komatsu N, Usuki K, Ichikawa M, and Kurokawa M.
    Spectrum of clinical and genetic features of patients with inherited platelet disorder with suspected predisposition to hematological malignancies: a nationwide survey in Japan.
    Ann Oncol 27(5):887-95, 2016.
    PMID: 26884589


このページの先頭へ




[2015年] >2018年 >2017年 >2016年 >2014年 >2013年 >2012年 >2011年
  1. Arai S, Miyauchi M, and Kurokawa M.
    Modeling of hematologic malignancies by iPS technology.
    Exp Hematol 43(8):654-60, 2015.
    PMID: 26135030
  2. Hangai S, Nannya Y, and Kurokawa M.
    Role of procalcitonin and C-reactive protein for discrimination between tumor fever and infection in patients with hematological diseases.
    Leuk Lymphoma 56: 910-4, 2015.
    PMID: 24991721
  3. Higo T, Miyagaki T, Nakamura F, Shinohara A, Asano H, Abe H, Senda N, Yoshizaki A, Fukayama M, and Kurokawa M.
    Paraneoplastic pemphigus occurring after bendamustine and rituximab therapy for relapsed follicular lymphoma.
    Ann Hematol 94: 683-5, 2015.
    PMID: 25199505
  4. Higo T, Kobayashi T, Yamazaki S, Ando S, Gonoi W, Ishida M, Okuma H, Nakamura F, Ushiku T, Ohtomo K, Fukayama M, and Kurokawa M.
    Cerebral embolism through hematogenous dissemination of pulmonary mucormycosis complicating relapsed leukemia.
    Int J Clin Exp Pathol 8(10):13639-42, 2015.
    PMID: 26722589
  5. Iizuka H, Kagoya Y, Kataoka K, Yoshimi A, Miyauchi M, Taoka K, Kumano K, Yamamoto T, Hotta A, Arai S, and Kurokawa M.
    Targeted gene correction of RUNX1 in induced pluripotent stem cells derived from familial platelet disorder with propensity to myeloid malignancy restores normal megakaryopoiesis.
    Exp Hematol 43(10):849-57, 2015.
    PMID: 26021490
  6. Kogure Y, Yoshimi A, Ueda K, Nannya Y, Ichikawa M, Nakamura F, and Kurokawa M.
    Modified ESHAP regimen for relapsed/refractory T cell lymphoma: a retrospective analysis.
    Ann Hematol 94: 989-94, 2015.
    PMID: 25687839
  7. Morita K, Masamoto Y, Kataoka K, Koya J, Kagoya Y, Yashiroda H, Sato T, Murata S, and Kurokawa M.
    BAALC potentiates oncogenic ERK pathway through interactions with MEKK1 and KLF4.
    Leukemia 29(11):2248-56, 2015.
    PMID: 26050649
  8. Nasu R, Nannya Y, and Kurokawa M.
    A randomized controlled study evaluating the efficacy of aprepitant for highly/moderately emetogenic chemotherapies in hematological malignancies.
    Int J Hematol 101: 376-85, 2015.
    PMID: 25644148
  9. Uni M, Shinohara A, Nukina A, Nakamura F, Nannya Y, Mizoguchi M, Okazaki M, Tatsuno K, Moriya K, and Kurokawa M.
    Successful management of Rothia aeria pneumonia during the peritransplant period: first reported case in allogeneic hematopoietic stem cell transplant.
    Leuk Lymphoma 56: 248-50, 2015.
    PMID: 24766467
  10. Uni M, Yoshimi A, Yamazaki S, Taoka K, Shinohara A, Nannya Y, Nakamura F, and Kurokawa M.
    Comparison of garenoxacin with levofloxacin as antimicrobial prophylaxis in acute myeloid leukemia.
    Jpn J Clin Oncol 45: 745-8, 2015.
    PMID: 25644148
  11. Uni M, Kagoya Y, Nannya Y, Nakamura F, and Kurokawa M.
    Central nervous system relapse in patients with diffuse large B-cell lymphoma: analysis of incidence and prognostic factors.
    Leuk Lymphoma 56: 1869-71, 2015.
    PMID: 25267182


このページの先頭へ




[2014年] >2018年 >2017年 >2016年 >2015年 >2013年 >2012年 >2011年
  1. Hangai S, Yoshimi A, Hosoi A, Matsusaka K, Ichikawa M, Fukayama M, and Kurokawa M.
    An indeterminate result of QuantiFERON-TB Gold In-Tube for miliary tuberculosis due to a high level of IFN-γ production.
    Int J Hematol 99: 523-6, 2014.
    PMID: 24481938
  2. Harada S, Yamazaki S, Nakamura F, Morita K, Yoshimi A, Shinozaki-Ushiku A, Fukayama M, and Kurokawa M.
    Autoimmune neutropenia preceding Helicobacter pylori-negative MALT lymphoma with nodal dissemination.
    Int J Clin Exp Pathol 7: 6386-90, 2014.
    PMID: 25337296
  3. Honda A, Nakamura F, Nannya Y, Shintani Y, Fukayama M, Ichikawa M, and Kurokawa M.
    Pulmonary lymphocyte-rich classical Hodgkin lymphoma with early response to ABVD therapy.
    Ann Hematol 93: 1073-4, 2014.
    PMID: 24173088
  4. Honda A, Yoshimi A, Ushiku T, Shinoda Y, Kawano H, Toya T, Kogure Y, Yamashita H, Kume H, Nannya Y, and Kurokawa M.
    Successful control of carcinoma of unknown primary with axitinib, a novel molecular-targeted agent: a case report.
    Chemotherapy 60(5-6):342-5, 2014.
    PMID: 26288144
  5. Hosoi M, Kumano K, Taoka K, Arai S, Kataoka K, Ueda K, Kamikubo Y, Takayama N, Otsu M, Eto K, Nakauchi H, and Kurokawa M.
    Generation of induced pluripotent stem cells derived from primary and secondary myelofibrosis patient samples.
    Exp Hematol 42: 816-25, 2014.
    PMID: 24859480
  6. Kagoya Y, Yoshimi A, Kataoka K, Nakagawa M, Kumano K, Arai S, Kobayashi H, Saito T, Iwakura Y, and Kurokawa M.
    NF-κB/TNF-α positive feedback loop with active proteasome machinery supports myeloid leukemia initiating cell capacity.
    J Clin Invest 124:528-42, 2014.
    PMID: 24382349
  7. Kagoya Y, Yoshimi A, Tsuruta-Kishino T, Arai S, Satoh T, Akira S, and Kurokawa M.
    JAK2V617F-positive myeloproliferative neoplasm clones evoke paracrine DNA damage to adjacent normal cells through secretion of lipocalin-2.
    Blood 124: 2996-3006, 2014.
    PMID: 25217696
  8. Kagoya Y, Nannya Y, Nakamura F, and Kurokawa M.
    Gene expression profiles of central nervous system lymphoma predict poor survival in patients with diffuse large B-cell lymphoma.
    Br J Haematol 166: 794-7, 2014.
    PMID: 24749697
  9. Kobayashi T, Seo S, Morita S, Goto A, Masuda A, Shimizu N, Nishida M, Nunobe S, Ichikawa M, Takazawa Y, Seto Y, Fukayama M, and Kurokawa M.
    Esophageal intramucosal hematoma after peripheral blood stem cell transplantation: case report and review of literature.
    Int J Clin Exp Pathol 7: 2690-4, 2014.
    PMID: 24966988
  10. Kogure Y, Nakamura F, Nukina A, Kamikubo Y, Ichikawa M, Kamikubo Y, and Kurokawa M.
    Catheter-related septic shock by Micrococcus in an autologous hematopoietic stem cell transplantation recipient.
    Am J Infect Control 42: 87, 2014.
    PMID: 24388476
  11. Kogure Y, Nakamura F, Shinozaki-Ushiku A, Watanabe A, Kamei K, Yoshizato T, Nannya Y, Fukayama M, and Kurokawa M.
    Pulmonary mucormycosis with embolism: two autopsied cases of acute myeloid leukemia.
    Int J Clin Exp Pathol 7: 3449-53, 2014.
    PMID: 25031775
  12. Nakazaki K, Nannya Y, and Kurokawa M.
    Distribution of serum erythropoietin levels in lower risk myelodysplastic syndrome cases with anemia.
    Int J Hematol 99: 53-6, 2014.
    PMID: 24307517
  13. Nannya Y, Shinohara A, Ichikawa M, and Kurokawa M.
    Serial profile of vitamins and trace elements during the acute phase of allogeneic stem cell transplantation.
    Biol Blood Marrow Transplant 20: 430-4, 2014.
    PMID: 24333749
  14. Nasu R, Nannya Y, Shinohara A, Ichikawa M, and Kurokawa M.
    Favorable outcomes of tacrolimus compared with cyclosporine A for GVHD prophylaxis in HSCT for standard-risk hematological diseases.
    Ann Hematol 93: 1215-23, 2014.
    PMID: 24590535
  15. Nishikawa S, Arai S, Masamoto Y, Kagoya Y, Toya T, Watanabe-Okochi N, and Kurokawa M.
    Thrombopoietin/MPL signaling confers growth and survival capacity to CD41-positive cells in a mouse model of Evi1 leukemia.
    Blood 124: 3587-96, 2014.
    PMID: 25298035
  16. Nukina A, Kagoya Y, Watanabe-Okochi N, Arai S, Ueda K, Yoshimi A, Nannya Y, and Kurokawa M.
    Single-cell gene expression analysis reveals clonal architecture of blast-phase chronic myeloid leukaemia.
    Br J Haematol 165: 414-6, 2014.
    PMID: 24401018
  17. Ogura M, Ichikawa M, Masuda A, Kandabashi K, Nannya Y, and Kurokawa M.
    A mixed-type autoimmune hemolytic anemia with immune thrombocytopenia related with myositis and post-transplantation lymphoproliferative disorder.
    Ann Hematol 93: 869-71, 2014.
    PMID: 24013519
  18. Sato T, Goyama S, Kataoka K, Nasu R, Tsuruta-Kishino T, Kagoya Y, Nukina A, Kumagai K, Kubota N, Nakagawa M, Arai S, Yoshimi A, Honda H, Kadowaki T, and Kurokawa M.
    Evi1 defines leukemia-initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
    Oncogene 33: 5028-38, 2014.
    PMID: 24747972
  19. Satoh Y, Masuda A, Jona M, Nannya Y, Yokota H, Kurokawa M, and Yatomi Y.
    Heparin-mediated inhibition of PCR in the accelerated phase of chronic myeloid leukaemia characterized by abundant basophilia.
    Eur J Haematol 92: 456-7, 2014.
    PMID: 24373003
  20. Shinohara A, Imai Y, Nakagawa M, Takahashi T, Ichikawa M, and Kurokawa M.
    Intracellular reactive oxygen species mark and influence the megakaryocyte-erythrocyte progenitor fate of common myeloid progenitors.
    Stem Cells 32: 548-57, 2014.
  21. Takaoka K, Nannya Y, Shinohara A, Arai S, Nakamura F, and Kurokawa M.
    A novel scoring system to predict the incidence of invasive fungal disease in salvage chemotherapies for malignant lymphoma.
    Ann Hematol 93: 1637-44, 2014.
    PMID: 24908330
  22. Toya T, Yoshimi A, Morioka T, Arai S, Ichikawa M, Usuki K, and Kurokawa M.
    Development of hairy cell leukemia in familial platelet disorder with predisposition to acute myeloid leukemia.
    Platelets 25: 300-2, 2014.
    PMID: 23971860
  23. Tsukamoto A, Nakamura F, Nannya Y, Kobayashi Y, Shibahara J, Ichikawa M, Fukayama M, Koike K, and Kurokawa M.
    MALT lymphoma of the small bowel with protein-losing enteropathy.
    Int J Hematol.
    99: 198-201, 2014.
    PMID: 24395281
  24. Tsukamoto A, Yoshiki Y, Yamazaki S, Kumano K, Nakamura F, and Kurokawa M.
    The significance of free light chain measurements in the diagnosis of myelomatous pleural effusion.
    Ann Hematol 93: 507-8, 2014.
    PMID: 23797638
  25. Ueda K, Yoshimi A, Kagoya Y, Nishikawa S, Marquez VE, Nakagawa M, and Kurokawa M.
    Inhibition of histone methyltransferase EZH2 depletes leukemia stem cell of mixed lineage leukemia fusion leukemia through upregulation of p16.
    Cancer Sci 105: 512-9, 2014.
    PMID: 24612037
  26. Yamazaki S, Nakamura F, Yoshimi A, Ichikawa M, Nannya Y, and Kurokawa M.
    Safety of high-dose micafungin for patients with hematological diseases.
    Leuk Lymphoma 55: 2572-6, 2014.
    PMID: 24460099
  27. Yoshimi A, Toya T, Kawazu M, Ueno T, Tsukamoto T, Iizuka H, Nakagawa M, Nannya Y, Arai S, Harada H, Usuki K, Hayashi Y, Ito E, Kirito K, Nakajima H, Ichikawa M, Mano H, and Kurokawa M.
    Recurrent CDC25C mutations drive malignant transformation in FPD/AML.
    Nature Commun 5: 4770, 2014.
    PMID: 25159113


このページの先頭へ




[2013年] >2018年 >2017年 >2016年 >2015年 >2014年 >2012年 >2011年
  1. Goyama S, Schibler J, Cunningham L, Zhang Y, Rao Y, Nishimoto N, Nakagawa M, Olsson A, Wunderlich M, Link KA, Mizukawa B, Grimes HL, Kurokawa M, Liu PP, Huang G, and Mulloy JC.
    Transcription factor RUNX1 promotes survival of acute myeloid leukemia cells.
    J Clin Invest 123: 3876-88, 2013.
  2. Hangai S, Nakamura F, Kamikubo Y, Honda A, Arai S, Nakagawa M, Ichikawa M, and Kurokawa M.
    Erythroleukemia showing early erythroid and cytogenetic responses to azacitidine therapy.
    Ann Hematol 92: 707-9, 2013.
  3. Hangai S, Nakamura F, Kamikubo Y, Ichikawa M, Suzuki H, Yoshida S, Yamada A, Takazawa Y, Fukayama M, Koike K, and Kurokawa M.
    Primary gastrointestinal follicular lymphoma with histological transformation.
    Ann Hematol 92: 993-4, 2013.
  4. Ichikawa M, Yoshimi A, Nakagawa M, Nishimoto N, Watanabe-Okochi N, and Kurokawa M.
    A role for RUNX1 in hematopoiesis and myeloid leukemia.
    Int J Hematol 97: 726-34, 2013.
  5. Kobayashi T, Ichikawa M, Kamikubo Y, and Kurokawa M.
    Acute myeloid leukemia with cryptic CBFB-MYH11 type D.
    Int J Clin Exp Pathol 6: 110-2, 2013.
  6. Kobayashi T, Hangaishi A, Yamamoto G, Shinohara A, Morikawa T, Takazawa Y, Ota S, Imai Y, Nakamura F, and Kurokawa M.
    Successful treatment of secondary NK/T-cell lymphoma of the testis.
    Ann Hematol 92: 997-8, 2013.
  7. Kobayashi T, Ichikawa M, Nannya Y, and Kurokawa M.
    The effect of decreased-dose idarubicin for elderly patients with acute myeloid leukemia.
    Jpn J Clin Oncol 43: 1047-51, 2013.
  8. Koya J, Nannya Y, Kobayashi H, Okugawa S, Moriya K, and Kurokawa M.
    Simultaneous increase in 1,3-β-D-glucan and procalcitonin levels in Pseudomonas aeruginosa infection.
    J Infect 67: 164-6, 2013.
  9. Kumano K, Arai S, and Kurokawa M.
    Generation of iPS cells from normal and malignant hematopoietic cells.
    Int J Hematol 98: 145-52, 2013.
  10. Morita K, Nannya Y, Yoshizato T, and Kurokawa M.
    Simple but powerful prognostic scoring model for MALT lymphoma: a retrospective study.
    Ann Hematol 92: 421-3, 2013.
  11. Morita K, Yoshimi A, Masuda A, Ichikawa M, Yatomi Y, and Kurokawa M.
    Unique association of Waldenström macroglobulinemia with optic neuritis and monoclonal T cell expansion.
    Int J Hematol 98: 247-9, 2013.
  12. Shinohara A, Yoshiki Y, Masamoto Y, Hangaishi A, Nannya Y, and Kurokawa M.
    Moxifloxacin is more effective than tosufloxacin in reducing chemotherapy-induced febrile neutropenia in patients with hematological malignancies.
    Leuk Lymphoma 54: 794-8, 2013.
  13. Toya T, Shinohara A, Tatsuno K, Seo S, Nannya Y, Ichikawa M, Makimura K, Moriya K, and Kurokawa M.
    A case of Schizophyllum commune sinusitis following unrelated cord blood transplantation for acute lymphoblastic leukemia.
    Int J Hematol 98: 261-3, 2013.
  14. Uni M, Yoshimi A, Nakamura F, Takazawa Y, Fukayama M, and Kurokawa M.
    Successful allogeneic stem cell transplantation for Lennert lymphoma.
    Ann Hematol 92: 859-60, 2013.
  15. Uni M, Yoshimi A, Maki H, Maeda D, Nakazaki K, Nakamura F, Fukayama M, and Kurokawa M.
    Successful treatment with recombinant thrombomodulin for B-cell lymphoma-associated hemophagocytic syndrome complicated by disseminated intravascular coagulation.
    Int J Clin Exp Pathol 6: 1190-4, 2013.
  16. Uni M, Nakamura F, Yoshimi A, Shinozaki-Ushiku A, Hosoi A, Nakazaki K, Nannya Y, Fukayama M, and Kurokawa M.
    Transformation of follicular lymphoma in the retroperitoneal muscles demonstrated by CT-guided needle biopsy of FDG-avid lesions: case series.
    Int J Clin Exp Pathol 15: 402-6, 2013.
    PMID: 24427363
  17. Watanabe-Okochi N, Yoshimi A, Sato T, Ikeda T, Kumano K, Taoka K, Satoh Y, Shinohara A, Tsuruta T, Masuda A, Yokota H, Yatomi Y, Takahashi K, Kitaura J, Kitamura T, and Kurokawa M.
    The shortest isoform of C/EBPβ, liver inhibitory protein (LIP), collaborates with Evi1 to induce AML in a mouse BMT model.
    Blood 121: 4142-55, 2013.
  18. Yoshizato T, Nannya Y, Imai Y, Ichikawa M, and Kurokawa M.
    Clinical significance of serum-soluble interleukin-2 receptor in patients with follicular lymphoma.
    Clin Lymphoma Myeloma Leuk 13: 410-6, 2013.
  19. Yoshizato T, Watanabe-Okochi N, Nannya Y, Ichikawa M, Takahashi T, Sato T, Masuda A, Yatomi Y, Tsuno NH, Kurokawa M, and Takahashi K.
    Prediction model for CD34 positive cell yield in peripheral blood stem cell collection on the fourth day after G-CSF administration in healthy donors.
    Int J Hematol 98: 56-65, 2013.


このページの先頭へ




[2012年] >2018年 >2017年 >2016年 >2015年 >2014年 >2013年 >2011年
  1. Fujioka Y, and Kurokawa M.
    Follicular lymphoma presenting with massive splenomegaly.
    Int J Hematol 95: 3-4, 2012.
  2. Goyama S, Takeuchi K, Kanda Y, Nannya Y, Chiba S, Fukayama M, and Kurokawa M.
    Post-transplant endothelial disorder after hematopoietic SCT: a blinded autopsy study.
    Bone Marrow Transplant 47: 1243-5, 2012.
  3. Hangai S, Nakamura F, Yamada A, Watabe H, Ichikawa M, Koike K, and Kurokawa M.
    Usefulness of double-balloon enteroscopy for evaluation of duodenal follicular lymphoma.
    Ann Hematol 91: 1819-20, 2012.
  4. Kagoya Y, Nannya Y, and Kurokawa M.
    Thalidomide maintenance therapy for patients with multiple myeloma: meta-analysis.
    Leuk Res 36: 1016-21, 2012.
  5. Kagoya Y, Seo S, Nannya Y, and Kurokawa M.
    Hyperlipidemia after allogeneic stem cell transplantation: prevalence, risk factors, and impact on prognosis.
    Clin Transplant 26: E168-75, 2012.
  6. Kataoka K, and Kurokawa M.
    Ecotropic viral integration site 1, stem cell self-renewal and leukemogenesis.
    Cancer Sci 103: 1371-7, 2012.
  7. Koya J, Iwata A, Nakamura F, Nagashima Y, Ichikawa M, Tsuji S, and Kurokawa M.
    Fludarabine may overcome resistance to rituximab in IgM-related neuropathy.
    J Neurol Sci 315: 150-2, 2012.
  8. Koya J, Nannya Y, Ichikawa M, and Kurokawa M.
    The clinical role of procalcitonin in hematopoietic SCT.
    Bone Marrow Transplant 47: 1326-31, 2012.
  9. Koya J, Nannya Y, and Kurokawa M.
    Evaluation of procalcitonin with liquid-phase binding assay in hematological malignancy.
    Clin Chim Acta 413: 1633-6, 2012.
  10. Kumano K, Arai S, Hosoi M, Taoka K, Takayama N, Otsu M, Nagae G, Ueda K, Nakazaki K, Kamikubo Y, Eto K, Aburatani H, Nakauchi H, and Kurokawa M.
    Generation of induced pluripotent stem cells from primary chronic myelogenous leukemia patient samples.
    Blood 119: 6234-42, 2012.
  11. Miyauchi M, Yoshimi A, Nannya Y, Takazawa Y, Ichikawa M, Fukayama M, and Kurokawa M.
    Efficacy of pleural biopsy for diagnosis of pleural effusion due to chronic GVHD after hematopoietic stem cell transplantation.
    Int J Hematol 96: 146-8, 2012.
  12. Morita K, Nakamura F, Kamikubo Y, Mizuno N, Miyauchi M, Yamamoto G, Nannya Y, Ichikawa M, and Kurokawa M.
    Pituitary lymphoma developing within pituitary adenoma.
    Int J Hematol 95: 721-4, 2012.
  13. Morita K, Nakamura F, Nannya Y, Kamikubo Y, Ichikawa M, and Kurokawa M.
    Lymphoma with specific affinity to endocrine organs.
    Ann Hematol 91: 1149-50, 2012.
  14. Morita K, Nakamura F, Nannya Y, Nomiya A, Arai S, Ichikawa M, Maeda D, Homma Y, and Kurokawa M.
    Primary MALT lymphoma of the urinary bladder in the background of interstitial cystitis.
    Ann Hematol 91: 1505-6, 2012.
  15. Nakazaki K, Hosoi M, Hangaishi A, Ichikawa M, Nannya Y, and Kurokawa M.
    Comparison between pulsed high-dose dexamethasone and daily corticosteroid therapy for adult primary immune thrombocytopenia: a retrospective study.
    Intern Med 51: 859-63, 2012.
  16. Taoka K, Kumano K, Nakamura F, Hosoi M, Goyama S, Imai Y, Hangaishi A, and Kurokawa M.
    The effect of iron overload and chelation on erythroid differentiation.
    Int J Hematol 95: 149-59, 2012.
  17. Taoka K, Yamamoto G, Kaburaki T, Takahashi T, Araie M, and Kurokawa M.
    Treatment of primary intraocular lymphoma with rituximab, high dose methotrexate, procarbazine, and vincristine chemotherapy, reduced whole-brain radiotherapy, and local ocular therapy.
    Br J Haematol 157: 252-4, 2012.
  18. Toya T, Nannya Y, Narukawa K, Ichikawa M, and Kurokawa M.
    A comparative analysis of meropenem and doripenem in febrile patients with hematologic malignancies: a single-center retrospective study.
    Jpn J Infect Dis 65: 228-32, 2012.
  19. Toya T, Nishimoto N, Koya J, Nakagawa M, Nakamura F, Kandabashi K, Yamamoto G, Nannya Y, Ichikawa M, and Kurokawa M.
    The first case of blastic plasmacytoid dendritic cell neoplasm with MLL-ENL rearrangement.
    Leuk Res 36: 117-8, 2012.
  20. Yamamoto G, Hosoi M, Miyagawa T, Ohmatsu H, Ichikawa M, Sugaya M, and Kurokawa M.
    Evans syndrome with cytomegalovirus infection followed by emerging peripheral T-cell lymphoma.
    Ann Hematol 91: 123-4, 2012.
  21. Yamazaki S, Nakamura F, Nannya Y, Nakagawa M, Ichikawa M, and Kurokawa M.
    Early-onset therapy-related myelodysplastic syndrome originating from prolonged myelosuppression after fludarabine-based therapy.
    Intern Med 51: 3427-30, 2012.
  22. Yoshiki Y, Yamamoto G, Takazawa Y, Nannya Y, Ishida J, Nagai R, Fukayama M, and Kurokawa M.
    AL amyloidosis with severe gastrointestinal invasion and acute obstructive suppurative cholangitis.
    Ann Hematol 91: 467-8, 2012.
  23. Yoshimi A, Yamamoto G, Goto T, Koike K, and Kurokawa M.
    Hepatocellular carcinoma in cirrhotic liver with graft-versus-host disease.
    Ann Hematol 91: 1501-2, 2012.
  24. Yoshimi M, Goyama S, Kawazu M, Nakagawa M, Ichikawa M, Imai Y, Kumano K, Asai T, Mulloy JC, Kraft AS, Takahashi T, Shirafuji N, and Kurokawa M.
    Multiple phosphorylation sites are important for RUNX1 activity in early hematopoiesis and T-cell differentiation.
    Eur J Immunol 42: 1044-50, 2012.


このページの先頭へ




[2011年] >2018年 >2017年 >2016年 >2015年 >2014年 >2013年 >2012年
  1. Arai S, Yoshimi A, Shimabe M, Ichikawa M, Nakagawa M, Imai Y, Goyama S, and Kurokawa M.
    Evi-1 is a transcriptional target of mixed-lineage leukemia oncoproteins in hematopoietic stem cells.
    Blood 117: 6304-14, 2011.
  2. Kagoya Y, Kataoka K, Nannya Y, and Kurokawa M.
    Pretransplant predictors and posttransplant sequels of acute kidney injury after allogeneic stem cell transplantation.
    Biol Blood Marrow Transplant 17: 394-400, 2011.
  3. Kagoya Y, Takahashi T, Nannya Y, Shinozaki A, Ota S, Fukayama M, and Kurokawa M.
    Hyperbilirubinemia after hematopoietic stem cell transplantation: comparison of clinical and pathologic findings in 41 autopsied cases.
    Clin Transplant 25: E552-7, 2011.
  4. Kagoya Y, Takahashi T, Yoshimoto T, Ichikawa M, Hangaishi A, Fukayama M, and Kurokawa M.
    Recurrent pericardial effusion after treatment for primary effusion lymphoma-like lymphoma: an autopsied case.
    Ann Hematol 90: 219-20, 2011.
  5. Kataoka K, Sato T, Yoshimi A, Goyama S, Tsuruta T, Kobayashi H, Shimabe M, Arai S, Nakagawa M, Imai Y, Kumano K, Kumagai K, Kubota N, Kadowaki T, and Kurokawa M.
    Evi1 is essential for hematopoietic stem cell self-renewal, and its expression marks hematopoietic cells with long-term multilineage repopulating activity.
    J Exp Med 208: 2403-16, 2011.
  6. Kobayashi CI, Yamamoto G, Hayashi A, Ota S, Imai Y, Fukayama M, and Kurokawa M.
    Fatal amebic colitis after high-dose dexamethasone therapy for newly diagnosed multiple myeloma.
    Ann Hematol 90: 225-6, 2011.
  7. Kobayashi H, Ichikawa M, Hangaishi A, Imai Y, and Kurokawa M.
    Concurrent development of "Burkitt-like" lymphoma and BCL-2-rearranged low-grade B cell lymphoma sharing the same germinal center origin.
    Int J Hematol 93: 112-7, 2011.
  8. Koya J, Nannya Y, Yoshizato T, Ono K, Seo S, Nakagawa M, Ichikawa M, and Kurokawa M.
    Disseminated tuberculosis following unrelated cord blood transplantation for refractory peripheral T-cell lymphoma: Clinical role of serum procalcitonin levels.
    J Infect 62: 237-40, 2011.
  9. Masamoto Y, Nannya Y, and Kurokawa M.
    Voriconazole is effective as secondary antifungal prophylaxis in leukemia patients with prior pulmonary fungal disease: case series and review of literature.
    J Chemother 23: 17-23, 2011.
  10. Nakagawa M, Shimabe M, Watanabe-Okochi N, Arai S, Yoshimi A, Shinohara A, Nishimoto N, Kataoka K, Sato T, Kumano K, Nannya Y, Ichikawa M, Imai Y, and Kurokawa M.
    AML1/RUNX1 functions as a cytoplasmic attenuator of NF-κB signaling in the repression of myeloid tumors.
    Blood 118: 6626-37, 2011.
  11. Nannya Y, Kataoka K, Hangaishi A, Imai Y, Takahashi T, and Kurokawa M.
    The negative impact of female donor/male recipient combination in allogeneic hematopoietic stem cell transplantation depends on disease risk.
    Transpl Int 24: 469-76, 2011.
  12. Nishimoto N, Arai S, Ichikawa M, Nakagawa M, Goyama S, Kumano K, Takahashi T, Kamikubo Y, Imai Y, and Kurokawa M.
    Loss of AML1/Runx1 accelerates the development of MLL-ENL leukemia through down-regulation of p19ARF.
    Blood 118: 2541-50, 2011.
  13. Ogura M, Todo T, Tanaka M, Nannya Y, Ichikawa M, Nakamura F, and Kurokawa M.
    Temozolomide may induce therapy-related acute lymphoblastic leukaemia.
    Br J Haematol 154: 663-5, 2011.
  14. Seo S, Nakamoto T, Takeshita M, Lu J, Sato T, Suzuki T, Kamikubo Y, Ichikawa M, Noda M, Ogawa S, Honda H, Oda H, and Kurokawa M.
    Crk-associated substrate lymphocyte type regulates myeloid cell motility and suppresses the progression of leukemia induced by p210Bcr/Abl.
    Cancer Sci 102: 2109-17, 2011.
  15. Yamamoto G, Maki H, Ichikawa M, and Kurokawa M.
    Pure red cell aplasia with follicular lymphoma showing regression and progression parallel to lymphoma.
    Int J Hematol 94: 576-7, 2011.
  16. Yamazaki S, Fujioka Y, Nakamura F, Ota S, Shinozaki A, Yamamoto G, Kamikubo Y, Nannya Y, Ichikawa M, Fukayama M, and Kurokawa M.
    Composite diffuse large B-cell lymphoma and CD20-positive peripheral T-cell lymphoma.
    Pathol Int 61: 662-6, 2011.
  17. Yamazaki S, Nakamura F, Nasu R, Nannya Y, Ichikawa M, and Kurokawa M.
    Haemophagocytic lymphohistiocytosis is a recurrent and specific complication of acute erythroid leukaemia.
    Br J Haematol 153: 669-72, 2011.
  18. Yoshiki Y, Asai T, Ichikawa M, Hangaishi A, Ota S, Imai Y, Takahashi T, and Kurokawa M.
    A case of myeloid sarcoma with correlation to JAK2V617F mutation, complicated by myelofibrosis and secondary acute myeloid leukemia.
    Intern Med 50: 2649-52, 2011.
  19. Yoshimi A, Goyama S, Watanabe-Okochi N, Yoshiki Y, Nannya Y, Nitta E, Arai S, Sato T, Shimabe M, Nakagawa M, Imai Y, Kitamura T, and Kurokawa M.
    Evi1 represses PTEN expression and activates PI3K/AKT/mTOR via interactions with polycomb proteins.
    Blood 117: 3617-28, 2011.
  20. Yoshimi A, and Kurokawa M.
    Evi1 forms a bridge between the epigenetic machinery and signaling pathways.
    Oncotarget 2: 575-86, 2011.
  21. Yoshimi A, and Kurokawa M.
    Key roles of histone methyltransferase and demethylase in leukemogenesis.
    J Cell Biochem 112: 415-24, 2011.
  22. Yoshizato T, Nannya Y, Yoshiki Y, Nakamura F, Imai Y, Ichikawa M, and Kurokawa M.
    Nilotinib-induced hypothyroidism in a patient with chronic myeloid leukemia.
    Int J Hematol 93: 400-2, 2011.


このページの先頭へ





  • 論文リスト
  • 臨床研究
  • 基礎研究



このページの先頭へ